How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,524 results for

Alpha Adrenergic Antagonist

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Alpha and beta adrenergic blockade in hypertension. (Abstract)

Alpha and beta adrenergic blockade in hypertension. 4112366 1972 07 08 2017 09 20 0140-6736 1 7758 1972 May 06 Lancet (London, England) Lancet Alpha and beta adrenergic blockade in hypertension. 979-82 Beilin L J LJ Juel-Jensen B E BE eng Clinical Trial Journal Article Randomized Controlled Trial England Lancet 2985213R 0140-6736 0 Adrenergic alpha-Antagonists 0 Adrenergic beta-Antagonists 0 Drug Combinations 0 Placebos 0TTZ664R7Z Phenoxybenzamine 9Y8NXQ24VQ Propranolol AIM IM S Adrenergic (...) alpha-Antagonists administration & dosage Adrenergic beta-Antagonists administration & dosage Adult Blood Pressure Body Weight Clinical Trials as Topic Drug Antagonism Drug Combinations Female Humans Hypertension drug therapy Hypotension, Orthostatic etiology Male Middle Aged Phenoxybenzamine administration & dosage adverse effects Physical Exertion Placebos Posture Propranolol administration & dosage adverse effects Pulse 72175671 1972 5 6 1972 5 6 0 1 1972 5 6 0 0 ppublish 4112366 S0140-6736(72

1972 Lancet (London, England) Controlled trial quality: uncertain

22. Regulation of rabbit myometrial alpha adrenergic receptors by estrogen and progesterone. Full Text available with Trip Pro

Regulation of rabbit myometrial alpha adrenergic receptors by estrogen and progesterone. The effects of estrogen and progesterone on uterine alpha-adrenergic receptors were investigated by direct receptor-binding studies. Immature female rabbits were primed with estrogen by intramuscular injections for 4 days. Other rabbits were primed with progesterone by injections of estrogen for 4 days followed by injections of progesterone for 4 days. The alpha adrenergic antagonist, [3H (...) ]dihydroergocryptine, was used to directly assess the number and affinity of alpha adrenergic receptors in membranes derived from estrogen-and progesterone-primed uteri. Membranes from estrogen-primed uteri contained 257 +/- 52 fmol of [3H]dihydroergocryptine-binding sites per mg protein whereas membranes from progesterone-primed uteri contained 83 +/- 11 fmol of of binding sites per mg protein. This reduction of alpha adrenergic receptor-binding sites by progesterone was statistically significant (P less than

1977 Journal of Clinical Investigation

23. N-Aralkyl substitution increases the affinity of adrenergic drugs for the alpha-adrenoceptor in rat liver. Full Text available with Trip Pro

N-Aralkyl substitution increases the affinity of adrenergic drugs for the alpha-adrenoceptor in rat liver. 1 The alpha-adrenoceptor of rat liver plasma membranes was studied by use of the specific alpha-antagonist [3H]-dihydroergocryptine ([3H]-DHEC). Catecholamines and adrenergic compounds displayed an order of affinity that is typical of an alpha-receptor. Nevertheless, protokylol, a potent beta-adrenoceptor agonist, exhibited a higher affinity than that of adrenaline for alpha-sites (...) . This result might be due to its bulky substituent on the amino group. 2 Further displacement experiments between [3H]-DHEC and four pairs of drugs differently substituted on the amino group (isoprenaline vs Cc-25, orciprenaline vs fenoterol, AH 3474 vs labetalol, pindolol vs hydroxybenzylpindolol) provided evidence that N-alkyl substitution decreased the affinity for alpha-sites (20 micromolar less than KD less than 200 micromolar), whereas an N-aralkyl one increased the affinity (0.17 micromloar less

1979 British journal of pharmacology

24. Alpha blockers v calcium blockers to increase spontaneous passage of renal calculi

Therapy (MET) – but you don’t know whether to prescribe alpha-adrenergic antagonists or calcium channel blockers. Search Strategy Ovid MEDLINE 1946 to Nov week 2 2012 and Embase 1980 to 2012 Week 46 via OVIDSP interface. [adrenergic alpha antagonist.mp OR alpha blocker$.mp. OR tamsulosin.mp. OR flomax.mp. OR alfuzosin.mp. OR doxazosin.mp. OR terazosin.mp. OR silodosin.mp. OR calcium antagonist$.mp. calcium channel blocker.mp. OR nifedipine.mp. OR nimodipine.mp. OR amlodipine.mp. OR felodipine.mp (...) : 17th April 2013 Status: Green (complete) Three Part Question In [adult patients with urinary calculi] is [treatment with alpha receptor blockers superior to treatment with calcium channel antagonists] at [increasing the speed and success of spontaneous stone passage]? Clinical Scenario A 51 year old presents to A&E with loin pain and macroscopic haematuria and a diagnosis of renal calculi is made. The patient’s pain is adequately controlled and the decision is discharge with Medical Expulsive

2013 BestBETS

25. Beta Adrenergic Receptor

. Related Studies (from Trip Database) Ontology: Receptors, Adrenergic, beta-1 (C0001642) Definition (MSH) A subclass of beta-adrenergic receptors (RECEPTORS, ADRENERGIC, BETA). The adrenergic beta-1 receptors are equally sensitive to EPINEPHRINE and NOREPINEPHRINE and bind the agonist DOBUTAMINE and the antagonist METOPROLOL with high affinity. They are found in the HEART, juxtaglomerular cells, and in the central and peripheral nervous systems. Definition (NCI) Beta 1 adrenergic receptor protein (477 (...) adrenergic fibers, Beta Adrenergic Receptors are one of two major classes of adrenergic receptors (alpha and beta) based on their reactions to norepinephrine and epinephrine, on cellular effects of receptor activation, and on relative affinities and reactions to synthetic blocking or stimulating agents. Beta-adrenergic receptors respond to blocking agents such as propranolol and to activating agents such as isoproterenol. Beta-1 type receptors mediate lipolysis and increase cardiac rate and force

2018 FP Notebook

26. Treatment of Asian Flushing Syndrome With Topical Alpha Agonists

Flushing Alcohol-Related Disorders Skin Manifestations Signs and Symptoms Substance-Related Disorders Chemically-Induced Disorders Mental Disorders Brimonidine Tartrate Antihypertensive Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs (...) Treatment of Asian Flushing Syndrome With Topical Alpha Agonists Treatment of Asian Flushing Syndrome With Topical Alpha Agonists - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Treatment of Asian Flushing

2018 Clinical Trials

27. Effects of Alpha-1 Antagonist, Stress and Relaxation on Anorectal Functions

: January 11, 2019 Last Update Posted: January 29, 2019 Last Verified: January 2019 Layout table for additional information Studies a U.S. FDA-regulated Drug Product: Yes Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Constipation Signs and Symptoms, Digestive Signs and Symptoms Alfuzosin Adrenergic alpha-1 Receptor Antagonists Adrenergic alpha-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms (...) Effects of Alpha-1 Antagonist, Stress and Relaxation on Anorectal Functions Effects of Alpha-1 Antagonist, Stress and Relaxation on Anorectal Functions - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2013 Clinical Trials

28. Prazosin, a selective antagonist of post-synaptic alpha-adrenoceptors [proceedings]. Full Text available with Trip Pro

Prazosin, a selective antagonist of post-synaptic alpha-adrenoceptors [proceedings]. 14760 1977 05 20 2018 11 13 0007-1188 59 3 1977 Mar British journal of pharmacology Br. J. Pharmacol. Prazosin, a selective antagonist of post-synaptic alpha-adrenoceptors [proceedings]. 514P-515P Cambridge D D Davey M J MJ Massingham R R eng Journal Article England Br J Pharmacol 7502536 0007-1188 0 Adrenergic alpha-Antagonists 0 Quinazolines XM03YJ541D Prazosin IM Adrenergic alpha-Antagonists Animals In Vitro

1977 British journal of pharmacology

29. Profiles of alpha-adrenoceptor antagonists in the pitched rat [proceedings] Full Text available with Trip Pro

Profiles of alpha-adrenoceptor antagonists in the pitched rat [proceedings] 27278 1978 09 15 2018 11 13 0007-1188 63 2 1978 Jun British journal of pharmacology Br. J. Pharmacol. Profiles of alpha-adrenoceptor antagonists in the pitched rat [proceedings]. 401P-402P Doxey J C JC Easingwood R E RE eng Journal Article England Br J Pharmacol 7502536 0007-1188 0 Adrenergic alpha-Antagonists IM Adrenergic alpha-Antagonists pharmacology Animals Male Muscle Contraction drug effects Rats Spinal Cord

1978 British journal of pharmacology

30. β2-Adrenergic Receptor-Mediated HIF-1α Upregulation Mediates Blood Brain Barrier Damage in Acute Cerebral Ischemia Full Text available with Trip Pro

was accompanied by suppressed occludin degradation and vascular endothelial growth factor (VEGF) mRNA upregulation. Interestingly, β2-adrenergic receptor (β2-AR) antagonist ICI 118551 attenuated ischemia-induced BBB damage by regulating HIF-1α expression. Double immunostaining showed that HIF-1α was upregulated in ischemic neurons but not in astrocytes andendothelial cells. Of note, HIF-1α inhibition with inhibitor YC-1 or siRNA significantly prevented OGD-induced VEGF upregulation as well as the secretion (...) β2-Adrenergic Receptor-Mediated HIF-1α Upregulation Mediates Blood Brain Barrier Damage in Acute Cerebral Ischemia Disruption of the blood brain barrier (BBB) within the thrombolytic time window is an antecedent event to intracerebral hemorrhage in ischemic stroke. Our recent studies showed that 2-h cerebral ischemia induced BBB damage in non-infarcted area and secreted matrix metalloproteinase-2 (MMP-2) accounted for this disruption. However, the factors that affect MMP-2 secretion

2017 Frontiers in molecular neuroscience

31. Adrenergic System in Islet Transplantation

Propranolol Phentolamine Adrenergic Agents Adrenergic beta-Antagonists Adrenergic Antagonists Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Vasodilator Agents Adrenergic alpha-Antagonists (...) Adrenergic System in Islet Transplantation Adrenergic System in Islet Transplantation - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Adrenergic System in Islet Transplantation (Aim 1 Islets) The safety

2017 Clinical Trials

32. Beta Adrenergic Receptor Blockade as a Novel Therapy for Patients With Adenocarcinoma of the Prostate

by Histologic Type Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Genital Diseases, Male Prostatic Diseases Carvedilol Adrenergic Agents Adrenergic beta-Antagonists Adrenergic Antagonists Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Antihypertensive Agents Antioxidants Protective Agents Calcium Channel Blockers Membrane Transport Modulators Calcium-Regulating Hormones and Agents Vasodilator Agents Adrenergic alpha-1 Receptor (...) Antagonists Adrenergic alpha-Antagonists

2016 Clinical Trials

33. Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder

trial. JAMA 2006; 296: 2319-2328. Indexing Status Subject indexing assigned by NLM MeSH Adrenergic alpha-Antagonists /therapeutic use; Adult; Cohort Studies; Cost-Benefit Analysis; Drug Therapy, Combination /economics; Great Britain; Humans; Lower Urinary Tract Symptoms /drug therapy /etiology; Male; Middle Aged; Muscarinic Antagonists /therapeutic use; Prostatic Hyperplasia /complications; Quality of Life; State Medicine /economics; Urinary Bladder, Overactive /complications; Urination Disorders (...) Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder Estimating the quality-of-life impact and cost

2012 NHS Economic Evaluation Database.

34. Letter: Adrenergic-blocking drugs in hyperthyroidism. (Abstract)

Letter: Adrenergic-blocking drugs in hyperthyroidism. 4148614 1974 02 11 2013 11 21 0003-4819 79 6 1973 Dec Annals of internal medicine Ann. Intern. Med. Letter: Adrenergic-blocking drugs in hyperthyroidism. 899-900 Distiller L A LA Joffe B I BI Seftel H C HC eng Clinical Trial Journal Article Randomized Controlled Trial United States Ann Intern Med 0372351 0003-4819 0 Adrenergic alpha-Antagonists 0 Adrenergic beta-Antagonists 0 Benzyl Compounds 0 Guanidines 9Y8NXQ24VQ Propranolol SUG9176GRW (...) Practolol AIM IM Adrenergic alpha-Antagonists therapeutic use Adrenergic beta-Antagonists therapeutic use Benzyl Compounds administration & dosage adverse effects therapeutic use Drug Evaluation Guanidines administration & dosage adverse effects therapeutic use Heart Rate drug effects Humans Hyperthyroidism drug therapy Practolol administration & dosage therapeutic use Propranolol administration & dosage therapeutic use 1973 12 1 1973 12 1 0 1 1973 12 1 0 0 ppublish 4148614

1974 Annals of Internal Medicine Controlled trial quality: uncertain

35. Alpha Adrenergic Receptor

Receptors (CNS) Inhibits Locus Ceruleus reflex arc Peripheral vasodilatation V. Medications: Alpha Adrenergics Alpha Adrenergic Agonist (Alpha Adrenergic Receptor) Alpha Non-Specific Alpha 1 Selective Methoxamine Alpha 2 Selective (See ) Alpha-methylnorepinephrine Alpha Receptor Antagonist Alpha Non-Specific Phentolamine Alpha 1 Selective (See ) Phenoxybenzamine Alpha 2 Selective Tolazoline Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search (...) Alpha Adrenergic Receptor Alpha Adrenergic Receptor Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Alpha Adrenergic Receptor Alpha

2015 FP Notebook

36. The maturation of neuromuscular function in a multiply innervated structure: development of the longitudinal smooth muscle of the foetal mammalian gut and its cholinergic excitatory, adrenergic inhibitory, and non-adrenergic inhibitory innervation Full Text available with Trip Pro

of gestation. Both were also present in the mouse by the 16th day of gestation. Responsiveness of rabbit tissue to exogenous acetylcholine appeared together with the advent of a functional cholinergic innervation. Since excitatory responses were potentiated by eserine, the tissue was probably able to inactivate acetylcholine through hydrolysis mediated by cholinesterase. Early relaxant responses resisted blockade by adrenergic neurone blocking agents and by antagonists active at alpha- and beta (...) The maturation of neuromuscular function in a multiply innervated structure: development of the longitudinal smooth muscle of the foetal mammalian gut and its cholinergic excitatory, adrenergic inhibitory, and non-adrenergic inhibitory innervation 1. The earliest components of the developing innervation of the rabbit intestine to be detected in this study were the cholinergic excitatory and the intrinsic inhibitory innervation. These developed simultaneously in the rabbit at 17 days

1973 The Journal of physiology

37. Adrenergic and 'non-adrenergic' components in the contractile response of the vas deferens to a single indirect stimulus. Full Text available with Trip Pro

components were more rapid and briefer than the equivalent response of rat anococcygeus. 3. The second, slow component was abolished by alpha-adrenoceptor antagonist drugs, potentiated and prolonged by drugs which inhibit the neuronal uptake of noradrenaline and absent from tissues taken from rats pre-treated with reserpine, suggesting that the neurotransmitter for this component is noradrenaline. 4. These experiments were extended to the mouse or guinea-pig vas deferens. Both showed the same two (...) component mechanical response as the rat vas and in both the second, slow component was preferentially inhibited by alpha-adrenoceptor antagonists and potentiated by drugs blocking noradrenaline uptake. 5. Drugs known to reduce the response to repetitive nerve stimulation of the vas were examined for their effect on the response to a single stimulus. Lysergic acid diethylamide preferentially inhibited the second, slow phase of contraction whereas apomorphine preferentially inhibited the first rapid

1978 The Journal of physiology

38. Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment

Norepinephrine Anxiety Fear Stress Additional relevant MeSH terms: Layout table for MeSH terms Alcoholism Alcohol-Related Disorders Substance-Related Disorders Chemically-Induced Disorders Mental Disorders Prazosin Antihypertensive Agents Adrenergic alpha-1 Receptor Antagonists Adrenergic alpha-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs (...) Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Repurposing alpha1

2016 Clinical Trials

39. Pelvic floor muscle therapy or alpha-blocking agents for treatment of men with lower urinary tract symptoms: An exploratory randomized controlled trial. Full Text available with Trip Pro

of Groningen, Groningen, the Netherlands. Blanker Marco H MH Department of General Practice, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Dekker Janny H JH Department of General Practice, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. eng Journal Article 2017 03 22 Australia Int J Urol 9440237 0919-8172 Int J Urol. 2017 Jun;24(6):475 28503766 adrenergic alpha-1 receptor antagonists behavior therapy lower urinary tract (...) Pelvic floor muscle therapy or alpha-blocking agents for treatment of men with lower urinary tract symptoms: An exploratory randomized controlled trial. 28332234 2018 12 31 1442-2042 24 6 2017 06 International journal of urology : official journal of the Japanese Urological Association Int. J. Urol. Pelvic floor muscle therapy or alpha-blocking agents for treatment of men with lower urinary tract symptoms: An exploratory randomized controlled trial. 473-474 10.1111/iju.13339 Hut Jan J

2017 International journal of urology : official journal of the Japanese Urological Association Controlled trial quality: uncertain

40. Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasia Full Text available with Trip Pro

100968571 1471-2490 0 Adrenergic alpha-Antagonists 0 Muscarinic Antagonists IM Adrenergic alpha-Antagonists administration & dosage economics Aged Drug Therapy, Combination Health Care Costs trends Health Resources economics statistics & numerical data Humans Lower Urinary Tract Symptoms drug therapy economics epidemiology Male Middle Aged Muscarinic Antagonists administration & dosage economics Prostatic Hyperplasia drug therapy economics epidemiology Retrospective Studies Spain epidemiology (...) Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasia 28899370 2018 10 05 2018 12 02 1471-2490 17 1 2017 Sep 12 BMC urology BMC Urol Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasia. 83 10.1186/s12894

2017 BMC urology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>